Craneware (CRW) AI Stock Analysis

• Market Cap: £813.66M
• Dividend Yield: 1.27%
• Average Volume (3M): 124.42K
• Price to Earnings (P/E): 53.4
• Beta (1Y): 0.57
• Revenue Growth: 5.74%
• EPS Growth: 63.23%
• Country: UK
• Employees: 747
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.27
• Shares Outstanding: 35,431,866
• 10 Day Avg. Volume: 105,397
• 30 Day Avg. Volume: 124,416
• PEG Ratio: 0.76
• Price to Book (P/B): 3.07
• Price to Sales (P/S): 5.04
• P/FCF Ratio: 17.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £2,873.67
• Price Target Upside: 28.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 90.98
• Revenue Forecast (FY): £17.36B

• Rating: 64 Neutral
• Price Target: 2,408.00p ▲(7.98% Upside)

Craneware's overall stock score is primarily driven by its strong financial performance, with solid revenue growth and a robust balance sheet. However, technical indicators suggest potential short-term weakness, and the high P/E ratio indicates possible overvaluation. The absence of earnings call data and corporate events means these factors do not influence the score.

Craneware Business Overview & Revenue Model

Company Description

Craneware (CRW) is a leading provider of revenue integrity solutions for the healthcare sector, primarily focusing on optimizing the financial performance of healthcare providers in the United States. The company specializes in software solutions that help hospitals and health systems manage their revenue cycles, ensuring accurate billing and compliance with complex regulations. Core products include Chargemaster Toolkit, Revenue Cycle Analytics, and other related services that streamline operations and enhance financial outcomes for healthcare organizations.

How the Company Makes Money

Craneware generates revenue primarily through subscription-based software licenses, professional services, and ongoing support contracts. The company's key revenue streams include the sale of its software solutions, which are typically offered on a recurring subscription model, allowing for predictable revenue generation. Additionally, Craneware earns income from consulting services that assist healthcare providers in implementing and optimizing their software solutions. Strategic partnerships with healthcare organizations and technology firms also play a crucial role in driving sales and expanding its customer base. The continuous demand for improved revenue cycle management due to regulatory changes and the increasing complexity of healthcare billing further contributes to Craneware's earnings.

Craneware Financial Statement Overview

Summary

Craneware demonstrates strong revenue growth and operational efficiency, supported by a solid balance sheet with low leverage. However, there are areas for improvement in net profitability and cash flow generation. The company is well-positioned in its industry but should focus on enhancing shareholder returns and cash flow stability.

Income Statement

Craneware has shown consistent revenue growth with a 3.8% increase in the latest year, supported by strong gross profit margins above 85%. However, net profit margins have been relatively modest, reflecting potential cost pressures or investment in growth. The EBIT and EBITDA margins indicate healthy operational efficiency, though there is room for improvement in net profitability.

Balance Sheet

The company's balance sheet is strong, with a low debt-to-equity ratio of 0.09, indicating conservative leverage. The equity ratio is solid, reflecting a stable capital structure. However, the return on equity is relatively low, suggesting that the company could enhance its profitability to better utilize shareholder equity.

Cash Flow

Operating cash flow has been robust, but free cash flow growth has declined by 13.4% recently, which could be a concern if it continues. The operating cash flow to net income ratio is healthy, indicating good cash conversion, but the free cash flow to net income ratio suggests a need for improved cash generation relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	205.66M	205.66M	174.02M	189.27M	165.54M	75.58M
Gross Profit	179.27M	179.27M	148.44M	162.20M	142.37M	70.20M
EBITDA	38.80M	38.80M	51.60M	54.26M	47.54M	18.48M
Net Income	19.66M	19.66M	9.23M	11.70M	9.41M	12.90M
Balance Sheet
Total Assets	551.06M	551.06M	576.98M	543.65M	568.79M	311.60M
Cash, Cash Equivalents and Short-Term Investments	55.92M	55.92M	78.54M	34.59M	47.16M	235.62M
Total Debt	31.65M	31.65M	86.69M	40.15M	115.52M	2.20M
Total Liabilities	213.50M	213.50M	249.13M	215.06M	235.77M	51.32M
Stockholders Equity	337.56M	337.56M	327.84M	328.59M	333.02M	260.28M
Cash Flow
Free Cash Flow	59.41M	59.41M	83.20M	24.91M	12.93M	13.21M
Operating Cash Flow	59.90M	59.90M	98.75M	41.86M	26.96M	23.54M
Investing Cash Flow	-13.98M	-13.98M	-15.34M	-15.81M	-307.32M	-10.32M
Financing Cash Flow	-24.58M	-24.58M	-53.28M	-70.00M	91.90M	174.55M

Craneware Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2230.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Negative. The current price of 2230 is below the 20-day moving average (MA) of 2292.50, below the 50-day MA of 2296.00, and above the 200-day MA of 2074.15, indicating a neutral trend. The MACD of -12.59 indicates Positive momentum. The RSI at 45.75 is Neutral, neither overbought nor oversold. The STOCH value of 35.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CRW.

Craneware Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRW	64 Neutral	£813.66M	53.44	6.00%	1.27%	5.74%	63.23%
AMS	64 Neutral	£467.12M	50.82	3.66%	1.24%	68.03%	-18.27%
SPI	62 Neutral	£927.47M	50.11	2.51%	1.00%	6.95%	-34.38%
PRTC	59 Neutral	£310.32M	8.99	15.04%	―	1231.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONT	51 Neutral	£1.32B	-9.02	-26.01%	―	22.03%	20.01%

Craneware Corporate Events

Craneware Announces AGM and Directorate Change

Craneware plc has announced the posting of its Annual Report and Accounts for the year ending 30 June 2025, along with the Notice of Annual General Meeting (AGM) scheduled for 21 November 2025. David Kemp, the Senior Non-Executive Director and Chair of the Audit Committee, will retire from the Board on the day of the AGM, after nearly six years of service. The Board expressed gratitude for his contributions and will update on the recruitment of a new Independent Non-Executive Director.

The most recent analyst rating on (GB:CRW) stock is a Hold with a £2473.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware Updates Share Capital Following Employee Share Options

Craneware plc has updated its issued share capital following recent employee share option exercises, resulting in 35,431,867 Ordinary Shares with voting rights. This change in share capital is significant for shareholders as it affects calculations related to their interests under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:CRW) stock is a Hold with a £2473.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware Grants Long-Term Incentive Awards to Key Executives

Craneware plc announced the grant of conditional share awards under its Long Term Incentive Plan (2022) to key executives, including the CEO, CFO, CPO, and CLO. These awards are contingent on performance conditions related to shareholder return and earnings growth over a five-year period, with a two-year holding period post-vesting, reflecting the company’s commitment to aligning executive incentives with long-term shareholder value.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £2492.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware Reports Strong FY25 Results with Revenue and Profit Growth

Craneware plc reported strong financial results for FY25, with a 9% increase in revenue to $205.7 million and a 12% rise in adjusted EBITDA to $65.3 million. The company achieved significant growth in statutory profit before tax, up 52%, and improved customer retention rates, reflecting its strategic position in the US healthcare market. Craneware’s continued investment in R&D, successful integration of customer-facing teams, and alliance with Microsoft have reinforced its market leadership. The launch of AI-powered solutions and the transition of Trisus Platform revenues to recurring revenues are expected to drive further growth. The company’s outlook remains positive, with confidence in continued growth acceleration in FY26.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £2492.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware Enhances Financial Flexibility with Successful Refinancing

Craneware plc has successfully refinanced its banking facilities, enhancing its financial flexibility to support growth strategies. The new $100 million unsecured Revolving Credit Facility (RCF) offers improved terms and lower interest rates, consolidating previous loans and providing an additional $100 million accordion facility for potential mergers and acquisitions. This move, along with a proposed capital reduction to increase distributable reserves, positions Craneware to deliver shareholder returns and sustain its strong market position. The company reported positive trading results for the fiscal year ending June 2025, with increased revenue, profitability, and reduced debt, underscoring its robust financial health and strategic focus on growth in the U.S. healthcare market.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £2492.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware’s Capital Reduction Approved by Shareholders

Craneware plc announced the successful approval of resolutions at its General Meeting to reduce capital, which was supported by shareholders. This capital reduction, pending court approval, is part of Craneware’s strategic financial management to optimize its resources and enhance its market position. The move is expected to strengthen the company’s financial reserves, potentially benefiting stakeholders by improving financial flexibility and supporting future growth initiatives.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £2492.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware Shareholders Approve Capital Reduction Resolutions

Craneware plc announced that shareholders approved resolutions for a proposed capital reduction at a recent general meeting. The capital reduction, which requires court confirmation, involves capitalizing the merger reserve, allotting and canceling B ordinary shares, and crediting the reductions to company reserves. This move is expected to streamline the company’s financial structure and enhance operational efficiency, potentially impacting stakeholders positively by optimizing financial resources.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £2492.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Craneware Proposes Capital Reduction to Boost Shareholder Returns

Craneware plc has announced a proposed reduction of capital, which involves the cancellation of its share premium account and the capitalisation of its merger reserve. This strategic move, pending shareholder and court approval, aims to create distributable reserves of approximately $284 million, providing the company with increased flexibility for shareholder returns. The reduction of capital will not affect the company’s net assets, indicating a strategic financial maneuver to enhance shareholder value without impacting the company’s operational stability.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £54.50 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.